Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

PRICED: Alloheim E925m sr sec 2-part, E525m 7NC1 FRN E+362.5bp at 100; E400m 7NC3 fixed 5.625% at 100

HYC European Market: Deal Flow - General

Cidron Atrium SE (Alloheim) (ALLOHE) EUR925m 144A/Reg S fixed/floating sr sec notes two-part. B2/B-/B- (stable/stable/positive).  Via GS (B&D FRN)/JPM (B&D fixed)/SEB jt glocos and physical books/Mizuho jt books. No reg rights. List ISE. NY law. CoC at 101. Denoms: 100kx1k.

- EUR 525m (from EUR500m minimum) FRN due 02/15/33 (7y). NC1 (02/15/27) (MWC B+50bp), then at 100. Pays Feb 15, May 15, Aug 15, Nov 15, starting 05/15/26 (Act/360). Denoms: 100kx1k. Reg S ISIN: XS3286656544. IPT: low-mid 400bp at par. Price talk: E+400bp area (+/- 12.5bp) at par. Final terms: EUR525m at E+362.5bp at par. Priced: 3mE+362.5bp (0% floor) at 100.

- EUR400m (from EUR300m minimum) fixed rate notes due 02/15/33 (7y). NC3 (02/15/29) (MWC B+50bp), then at 102.8125 02/15/29, 101.40625 02/15/20, 100 02/15/21. Equity claw: 3y 40% at 105.625. Special call: 10% per year the first 3 years at 103. Pays Feb 15 and Aug 15, starting 08/15/25 (30/360). Reg S ISIN: XS3286655736. Denoms: 100kx1k. IPT: low-mid 6s. Price talk: 6.00% area (+/- 0.125%). Final terms: EUR400m at 5.625%. Priced: 5.625% at 100. +301bp vs 2.30% 02/15/33.

Roadshow began 01/26 (investor call 12pm UKT 01/26). Books closed at 1:30pm UKT 01/28. Reconfirms were due by 3pm UKT 01/28. (Originally pricing 01/29). UOP: along with EUR10m, to refinance Alloheim's existing EUR860m EUR term loan B due 2028, and repay EUR45m drawn on its revolver. Biz: leading German nursing home operator offering high-quality stationary and ambulatory care services. HQ: Dusseldorf, Germany.

Evercall/DealRoadshow registration / slides link: https://evercall.co/oacc/37106.


We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.